



ISLHD CLINICAL TRIALS

Shoalhaven Cancer Care Centre February 2025

ISLHD CANCER CLINICAL TRIALS UNIT

**Shoalhaven Cancer Care
Centre**

**Shoalhaven District
Memorial Hospital**

**Corner of Scenic Drive &
North Street
Nowra NSW 2541**

Ph: 02 4253 4384

Fax: 02 4222 5085

**Email: ISLHD-
CancerClinicalTrials@health.
nsw.gov.au**

The Illawarra Shoalhaven Local Health District (ISLHD) Cancer Clinical Trials Unit has a specialist team of doctors, nurses, radiation therapists and allied health professionals supporting a comprehensive suite of clinical trials for our local community. We are based at Wollongong and Shoalhaven District Memorial Hospitals in the Illawarra Cancer Care Centre and Shoalhaven Cancer Care Centre.

Clinical trials contribute to evidence based practice, knowledge, development and improved patient care. They provide our patients the opportunity to access novel and potentially efficacious treatment for their cancer close to home.

We currently have trials open for patients with:

- Colorectal cancer
- Gynaecological neoplasms
- Multiple Myeloma
- Solid tumours
- Genomic profiling

REFERRAL OR CONSULTATION

To discuss your patient with an ISLHD Trials Clinician, please phone the Shoalhaven Cancer Care Centre on
02 4428 7400

ISLHD Clinical Trials

****CURRENTLY OPEN FOR RECRUITMENT****

Scan the QR Code for more information including eligibility criteria

GI/Biliary **OXTOX:** Can oxaliplatin neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer – a phase II randomised study.
****Closing soon****

Prof Chantrill
***Satellite site**



Gynae **PARAGON-II:** Phase II basket study of an aromatase inhibitor plus PI3KCA inhibitor or CDK4/6 inhibitor in women with hormone receptor positive recurrent/metastatic gynaecological neoplasms.
****Cohorts A, B, D, E, F (limited spots) only****

Dr Kasherman
***Satellite site**



Multiple Myeloma **CA057-001:** A phase 3, two-Stage, randomized, multi-center, open-label study comparing CC-92480, bortezomib and dexamethasone (480Vd) versus pomalidomide, bortezomib and dexamethasone (PVd) in subjects with relapsed or refractory multiple myeloma (RRMM)
****Part 2 open for enrolment****

Dr Parmar
***Satellite site**



MAGNETISM-7: A randomised, 2-arm, phase 3 study of elranatamab (PF-06863135) versus lenalidomide in patients with newly diagnosed multiple myeloma after undergoing autologous stem-cell transplantation
****Standard of care arm only****

Dr Cartwright
***Satellite site**



Solid Tumours **GeneScreen 5-FU:** DPYD genotype-guided dose personalisation for fluoropyrimidine prescribing in cancer. DPYD genotyping for adults with solid organ malignancies intended to receive 5-fluorouracil or capecitabine, and/or irinotecan chemotherapy.

Prof Chantrill




Genomic profiling **Omico CaSP:** Cancer Screening Program
CaSP is the screening program associated with Pro-SPeCT, and provides free Comprehensive Genomic Profiling to patients in Australia with incurable and advanced cancer, to identify potential matches for patients to clinical trials with new targeted therapies.

ISLHD
Oncologists



Patient's are referred to CaSP by their treating oncologist. Please include ISLHD-clinicaltrials-pathology@health.nsw.gov.au in the online referral form.



ISLHD Clinical Trials

****CURRENTLY OPEN FOR RECRUITMENT****

For further information regarding these trials at the Shoalhaven Cancer Care Centre you may also contact the trial coordinators as listed or email ISLHD-SCCC-CancerClinicalTrials@health.nsw.gov.au

<i>Trial Coordinator</i>	<i>Availability</i>	<i>Contact details</i>
Kyrie Rodgers	Mon-Thurs	02 4428 7516
Jamie Tomlinson	Thurs-Fri	02 4429 1676
Jillian DuBose	Mon-Fri	02 4429 1676 Jillian.DuBose@health.nsw.gov.au